Research statistics

Survodutide research: publications and trials

What has been published on Survodutide: PubMed publications, the kind of evidence they report and registered clinical trials. These are counts of research, not a judgment of whether Survodutide works or is safe. For what it is and what the studies found, see the Survodutide profile.
Automated weekly refresh · data through November 15, 2026

At a glance

Publications, all years

71

Since 2022

Publications in 2026 so far

31

Through November 15, 2026

Human clinical research

26.8%

19 of 71 classified

Registered clinical trials

35

ClinicalTrials.gov

Randomized controlled trials

12

Publications reporting an RCT in people

Systematic reviews and meta-analyses

11

Preclinical studies

9.9%

5 animal · 2 in vitro · 0 computational

Records that only mention it

18

Not counted above

Status in the library: In clinical trials. Groups: GLP-1 receptor agonists.

What to keep in mind

  • Some completed trials have neither posted results nor a linked results publication.

Publications by year

Survodutide publications by year and evidence

2022, Preclinical (animal, in vitro, computational): 1 of 12023, Human clinical research: 3 of 42023, Reviews and meta-analyses: 1 of 42024, Human clinical research: 3 of 142024, Preclinical (animal, in vitro, computational): 1 of 142024, Reviews and meta-analyses: 7 of 142024, Other and not yet classified: 3 of 142025, Human clinical research: 4 of 212025, Preclinical (animal, in vitro, computational): 1 of 212025, Reviews and meta-analyses: 13 of 212025, Other and not yet classified: 3 of 212026 (to date), Human clinical research: 9 of 312026 (to date), Preclinical (animal, in vitro, computational): 4 of 312026 (to date), Reviews and meta-analyses: 16 of 312026 (to date), Other and not yet classified: 2 of 31Human clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classified01020304020222023202420252026*
Counted PubMed publications by year of first publication. * 2026 runs to November 15, 2026. A larger bar is more publications, not stronger evidence.
Show the data
YearHuman clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classifiedTotal
202201001
202330104
2024317314
20254113321
2026 (to date)9416231

Study types

Review26
Randomized controlled trial12
Editorial, letter or other8
Meta-analysis7
Animal study5
Other clinical trial5
Systematic review4
In vitro study2
Observational human study2

Research areas

From MeSH major topics. A paper can be in several areas.

Metabolic health57
Obesity and weight management41
Gastrointestinal22
Endocrinology19
Cardiovascular8
Reproductive and sexual health2
Neurological and mental health1

Registered clinical trials

10 of 18 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.

Completed: 25 · Not yet recruiting: 4 · Active, not recruiting: 3 · Recruiting: 3
Phase 1: 19 · Phase 2: 4 · Phase 3: 12

TrialStatusPhaseStartedResults
ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver DiseaseNCT07850063 · 600 enrolledNot yet recruitingPhase 32026-11—
SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose WeightNCT07855900 · 350 enrolledNot yet recruitingPhase 32026-11—
SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose WeightNCT07850050 · 600 enrolledNot yet recruitingPhase 32026-10—
A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or ObesityNCT07768813 · 44 enrolledActive, not recruitingPhase 12026-09—
A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood SugarNCT07754461 · 600 enrolledRecruitingPhase 32026-08—
A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-like InjectorNCT07413913 · 56 enrolledCompletedPhase 12026-03—
Albuminuria Reduction Study With Survodutide Treatment in Kidney DiseaseNCT07206290 · 120 enrolledNot yet recruitingPhase 22026-03—
A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up by the BodyNCT07221591 · 100 enrolledCompletedPhase 12025-11—
A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up in the BodyNCT07071974 · 16 enrolledCompletedPhase 12025-07—
A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With ObesityNCT06745284 · 64 enrolledActive, not recruitingPhase 12025-03—
A Study in Healthy People to Compare How 3 Different Formulations of Survodutide Are Taken up in the BodyNCT06772532 · 30 enrolledCompletedPhase 12025-02—
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have CirrhosisNCT06632457 · 1,590 enrolledRecruitingPhase 32024-11—
A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the LiverNCT05202353 · 29 enrolledActive, not recruitingPhase 12024-11—
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver FibrosisNCT06632444 · 1,800 enrolledRecruitingPhase 32024-10—
A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or ObesityNCT06564441 · 34 enrolledCompletedPhase 12024-10—
A Study in Chinese People With Overweight or Obesity to Test How Different Doses of Survodutide Are Taken up in the BodyNCT06492135 · 30 enrolledCompletedPhase 12024-08—
A Study to Test How BI 456906 is Taken up in the Blood of People With and Without Kidney ProblemsNCT06352411 · 42 enrolledCompletedPhase 12024-05—
A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain ActivityNCT06352424 · 23 enrolledCompletedPhase 12024-04—
A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)NCT06309992 · 218 enrolledCompletedPhase 32024-04—
A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or ObesityNCT06200467 · 110 enrolledCompletedPhase 12024-03—
A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose WeightNCT06214741 · 307 enrolledCompletedPhase 32024-02—
A Study to Test Whether Survodutide Helps Japanese People Living With Obesity DiseaseNCT06176365 · 274 enrolledCompletedPhase 32024-01—
A Study in Women With Overweight or Obesity to Test Whether Different Doses of BI 456906 Influence the Amount of a Contraceptive in the BloodNCT05896384 · 32 enrolledCompletedPhase 12023-12—
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose WeightNCT06066528 · 755 enrolledCompletedPhase 32023-11—
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose WeightNCT06066515 · 726 enrolledCompletedPhase 32023-11—
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)NCT06077864 · 5,530 enrolledCompletedPhase 32023-11—
A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906NCT05751226 · 88 enrolledCompletedPhase 12023-04—
A Study in Healthy Men to Test How BI 456906 is Processed in the BodyNCT05421338 · 6 enrolledCompletedPhase 12022-07—
A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906NCT05296733 · 82 enrolledCompletedPhase 12022-04—
A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)NCT04771273 · 295 enrolledCompletedPhase 22021-04Posted
A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose WeightNCT04667377 · 387 enrolledCompletedPhase 22021-03Posted
A Study to Test How Different Doses of BI 456906 Are Tolerated in Japanese Men With a Body Mass Index (BMI) Between 23 and 40 kg/m2NCT04384081 · 37 enrolledCompletedPhase 12020-06—
A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.NCT04153929 · 413 enrolledCompletedPhase 22020-04Posted
A Study to Test Different Doses of BI 456906 in Patients With ObesityNCT03591718 · 131 enrolledCompletedPhase 12018-07—
Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 456906 in Healthy Male VolunteersNCT03175211 · 20 enrolledCompletedPhase 12017-06—

Human trials and evidence reviews

Meta-analyses, systematic reviews and trials in people, newest first.

  1. GLP-1/Glucagon Receptor Dual Agonists for Metabolic Dysfunction-Associated Steatohepatitis and Steatotic Liver Disease (MASH/MASLD): A Systematic Review and Meta-Analysis.

    Digestive diseases (Basel, Switzerland) · November 9, 2026 · Meta-analysis · cited 0 times · open access

    PMID 43002386 · DOI 10.1159/ddi/acnag020 · Reviews and meta-analyses

  2. Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis.

    Diabetes, obesity & metabolism · September 29, 2026 · Meta-analysis · cited 0 times · open access

    PMID 42811393 · DOI 10.1111/dom.71400 · Reviews and meta-analyses

  3. Histological efficacy of anti-diabetic agents in MASH and the mediating role of weight loss: A network meta-analysis.

    Diabetes, obesity & metabolism · October 8, 2025 · Meta-analysis · cited 5 times

    PMID 41063381 · DOI 10.1111/dom.70187 · Reviews and meta-analyses

  4. Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis.

    Diabetes, obesity & metabolism · September 8, 2025 · Meta-analysis · cited 2 times

    PMID 40922121 · DOI 10.1111/dom.70105 · Reviews and meta-analyses

  5. Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis.

    The Journal of clinical endocrinology and metabolism · September 1, 2025 · Meta-analysis · cited 45 times

    PMID 40489581 · DOI 10.1210/clinem/dgaf336 · Reviews and meta-analyses

  6. Evaluating the efficacy and safety of survodutide for obesity: a systematic review and meta-analysis of randomized controlled trials.

    Proceedings (Baylor University. Medical Center) · April 1, 2025 · Meta-analysis · cited 3 times · open access

    PMID 40557198 · DOI 10.1080/08998280.2025.2480512 · Reviews and meta-analyses

  7. Effect of survodutide, a glucagon and GLP-1 receptor dual agonist, on weight loss: a meta-analysis of randomized controlled trials.

    Diabetology & metabolic syndrome · November 6, 2024 · Meta-analysis · cited 8 times · open access

    PMID 39508238 · DOI 10.1186/s13098-024-01501-x · Reviews and meta-analyses

  8. Efficacy of pharmacotherapies in improving liver fibrosis among patients with MASLD and fibrosis stages of F1-F3: systematic review and network meta-analysis.

    Journal of translational medicine · May 26, 2026 · Systematic review · cited 0 times · open access

    PMID 42192439 · DOI 10.1186/s12967-026-08219-6 · Reviews and meta-analyses

  9. Comparative Analysis of Glucagon Receptor Agonists vs. Resmetirom in MASLD and MASH: Network Meta-Analysis of Clinical Trials.

    Endocrinology, diabetes & metabolism · January 1, 2026 · Systematic review · cited 2 times · open access

    PMID 41466530 · DOI 10.1002/edm2.70157 · Reviews and meta-analyses

  10. Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA.

    Obesity (Silver Spring, Md.) · July 20, 2025 · Systematic review · cited 19 times · open access

    PMID 40685589 · DOI 10.1002/oby.24360 · Reviews and meta-analyses

Most cited

By OpenAlex citation count. Citations measure attention, not quality or correctness.

  1. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.

    The New England journal of medicine · June 7, 2024 · Randomized controlled trial · cited 515 times · open access

    PMID 38847460 · DOI 10.1056/nejmoa2401755 · Human clinical research

  2. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.

    The lancet. Diabetes & endocrinology · February 5, 2024 · Randomized controlled trial · cited 232 times

    PMID 38330987 · DOI 10.1016/s2213-8587(23)00356-x · Human clinical research

  3. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy.

    Molecular metabolism · November 7, 2022 · Animal study · cited 147 times · open access

    PMID 36356832 · DOI 10.1016/j.molmet.2022.101633 · Animal studies

  4. Dose-response effects on HbA<sub>1c</sub> and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.

    Diabetologia · December 14, 2023 · Randomized controlled trial · cited 138 times · open access

    PMID 38095657 · DOI 10.1007/s00125-023-06053-9 · Human clinical research

  5. Therapeutic horizons in metabolic dysfunction-associated steatohepatitis.

    The Journal of clinical investigation · July 1, 2025 · Review · cited 73 times · open access

    PMID 40590228 · DOI 10.1172/jci186425 · Reviews and meta-analyses

Latest publications

  1. Cardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT): a double-blind, randomised, placebo-controlled, phase 3 trial.

    Lancet (London, England) · November 9, 2026 · Randomized controlled trial · cited 0 times

    PMID 43003106 · DOI 10.1016/s0140-6736(26)02140-9 · Human clinical research

  2. GLP-1/Glucagon Receptor Dual Agonists for Metabolic Dysfunction-Associated Steatohepatitis and Steatotic Liver Disease (MASH/MASLD): A Systematic Review and Meta-Analysis.

    Digestive diseases (Basel, Switzerland) · November 9, 2026 · Meta-analysis · cited 0 times · open access

    PMID 43002386 · DOI 10.1159/ddi/acnag020 · Reviews and meta-analyses

  3. Charcoal-Based Depletion Method to Improve Drug Tolerance in Neutralizing Antibody Assays for Therapeutic Peptides.

    The AAPS journal · October 30, 2026 · In vitro study · cited 0 times

    PMID 42963450 · DOI 10.1208/s12248-026-01311-1 · In vitro studies

  4. Interpreting Survodutide Renoprotection in a Hyperfiltration Model.

    Diabetes, obesity & metabolism · October 19, 2026 · Editorial, letter or other · cited 0 times

    PMID 42897119 · DOI 10.1111/dom.71467 · Commentary and other

  5. From pathophysiology to therapy: dual and triple agonists as a new frontier in metabolic dysfunction-associated steatotic liver disease.

    Frontiers in pharmacology · October 13, 2026 · Review · cited 0 times · open access

    PMID 42947668 · DOI 10.3389/fphar.2026.1784959 · Reviews and meta-analyses

  6. Does Survodutide Provide Renoprotection Beyond Its Metabolic and Haemodynamic Effects in Diabetic Kidney Disease?

    Diabetes, obesity & metabolism · October 12, 2026 · Editorial, letter or other · cited 0 times · open access

    PMID 42864267 · DOI 10.1111/dom.71446 · Commentary and other

  7. The Power of Two: Harnessing Dual Glucagon and Incretin Signaling for Treatment of Obesity and Metabolic Dysfunction-Associated Steatohepatitis-A Narrative Review with a Translational Focus.

    Obesity reviews : an official journal of the International Association for the Study of Obesity · October 11, 2026 · Review · cited 0 times · open access

    PMID 42860310 · DOI 10.1111/obr.70228 · Reviews and meta-analyses

  8. Survodutide for the treatment of obesity: Mechanistic rationale, clinical evidence, and remaining uncertainties.

    Contemporary clinical trials · October 2, 2026 · Review · cited 0 times

    PMID 42822760 · DOI 10.1016/j.cct.2026.108493 · Reviews and meta-analyses

  9. Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.

    The New England journal of medicine · October 1, 2026 · Randomized controlled trial · cited 0 times

    PMID 42820639 · DOI 10.1056/nejmoa2607219 · Human clinical research

  10. Nephroprotective Effects of the Dual GCGR/GLP-1R Agonist Survodutide in Hypertension-Accelerated Diabetic Kidney Disease.

    Diabetes, obesity & metabolism · October 1, 2026 · Animal study · cited 2 times · open access

    PMID 42823075 · DOI 10.1111/dom.71387 · Animal studies

Browse all 71 publications in the dashboard

How this is counted

PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology

Search terms: BI 456906; Survodutide

((TITLE_ABS:"BI 456906" OR CHEM:"BI 456906" OR TITLE_ABS:"BI456906" OR CHEM:"BI456906") OR (TITLE_ABS:"Survodutide" OR CHEM:"Survodutide")) AND SRC:MED

Cite this page

Peptide Library. (2026, November 16). Survodutide research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/survodutide